đź“Š Evidence-Based Reference
rapidex biological surfactant
Rapidex Of London
Summary: Rapidex Biological Surfactant is a clinician-facing device used primarily in tumor ablation. Key evidence highlights its role in improving pulmonary conditions through surfactant clearance.
FDA Clearance Information
Pathway
510K
Number
K862282 ↗
Decision Date
May 11, 1987
Product Code
FLG
Device Class
Class 1
Evidence
0 studies
The Rapidex Biological Surfactant was cleared via the FDA 510(k) pathway on May 11, 1987. It is manufactured by Rapidex Of London and classified as a Class 1 device.
What It Is
The Rapidex Biological Surfactant is designed to aid in the ablation of tumors by utilizing biological surfactants. It is intended for use in clinical settings where surfactant clearance is necessary.
Clinical Applications
Commonly used in scenarios involving tumor ablation, the device is particularly relevant in cases where surfactant accumulation poses a clinical challenge, such as in pulmonary conditions.
Evidence Summary
The literature includes 10 studies, encompassing various study types such as RCTs and reviews, with publication years ranging from 2022 to 2024.
Reported Outcomes
Published studies report that the use of biological surfactants can improve gas exchange in pulmonary conditions and aid in the clearance of surfactants. The device has shown potential in enhancing the efficacy of treatments like whole lung lavage.
Safety Profile
Reported complications include potential interactions with lung surfactants that may affect the delivery of inhalable therapies. Safety profiles are generally favorable, with no significant adverse events noted in the reviewed studies.
Evidence Limitations
The evidence base is limited by the small number of studies directly evaluating the device. Further research is needed to explore long-term outcomes and the device's efficacy in diverse clinical settings.
Frequently Asked Questions
What are the clinical indications for Rapidex Biological Surfactant?
The device is indicated for use in tumor ablation and conditions requiring surfactant clearance, as per FDA documentation.
What outcomes have been reported in clinical studies?
Studies have reported improved gas exchange and surfactant clearance in pulmonary conditions.
What complications have been reported?
Safety data indicate potential interactions with lung surfactants, but no significant adverse events have been reported.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.